ECCO2R as an Adjunct to NIV in AECOPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease (COPD) is one of the UKs commonest chronic diseases and is responsible for a significant number of acute hospital admissions. COPD is characterised by progressive destruction in the elastic tissue within the lung, causing respiratory failure. The clinical course of COPD is characterised by recurrent acute exacerbations (AECOPD), causing considerable morbidity and mortality. Patients with moderate to severe acute exacerbations present with increased work of breathing and hypercapnia. The standard for respiratory support in this setting is non-invasive ventilation (NIV), a management strategy underpinned by a considerable evidence base. However despite NIV, up to 30% of patients with AECOPD will 'fail' and require intubation and mechanical ventilation. The mortality rate for patients requiring NIV is approximately 4%, if conversion to mechanical ventilation occurs the mortality is 29%.

The last decade has seen an increasing interest in the provision of extracorporeal support for respiratory failure. The key element that has underpinned improving survival has been technological advancement. This has resulted in pumps causing less blood trauma and inflammatory response, better percutaneous cannulation techniques and coated circuits with reduced heparin requirements. Overall this has significantly reduced the complications associated with the provision of extracorporeal support. One variation of this technique (extra-corporeal CO2 removal ECCO2R) allows CO2 clearance from the blood. This approach has been the subject of a number of animal experiments and uncontrolled human case series demonstrating improved arterial CO2 and reduced work of breathing. Our own unpublished series demonstrates the same physiological changes. However to date the benefits of this approach have not been tested in a randomised controlled trial.

The hypothesis is that the addition of ECCO2R to NIV will shorten the duration of NIV and reduce likelihood of intubation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation

NCT02586948

Chronic Obstructive Pulmonary Disease

COMPLETED NA

ECCO2R in the Treatment of Acute Exacerbation of COPD With Severe Hypercapnia

NCT04842344

Lung Diseases, Obstructive

UNKNOWN NA

Extracorporeal CO2 Removal in Acute Exacerbation of COPD Not Responding to Non-Invasive Ventilation

NCT04882410

COPD Exacerbation Acute

COMPLETED

Extracorporeal Carbon Dioxide Removal in Severe Chronic Obstructive Pulmonary Disease Exacerbation

NCT03692117

COPD Exacerbation

UNKNOWN

ecco2R to facilitatE earLy libEration From mechanicAl Ventilation inpatientS With Copd Acute Exacerbation

NCT04147104

Acute Exacerbation of COPD

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NIV

Standard application of NIV in hypercapnic respiratory failure as per usual standard of care

Group Type ACTIVE_COMPARATOR

NIV

Intervention Type DEVICE

Standard care

ECCO2R

Addition of ECCO2R to NIV in AECOPD

Group Type EXPERIMENTAL

NIV

Intervention Type DEVICE

Standard care

ECCO2R

Intervention Type DEVICE

Application of ECCO2R in addition to NIV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NIV

Standard care

Intervention Type DEVICE

ECCO2R

Application of ECCO2R in addition to NIV

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Haemolung

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Known COPD with an acute exacerbation. An acute exacerbation is defined as per the GOLD criteria as an increase in dyspnoea, cough and/or sputum over the patient's normal symptoms. A severe exacerbation is defined as one requiring hospital admission.
* Patients with a persistent arterial pH\<7.30 due primarily to hypercapnic respiratory failure after standard medical therapy and at least 1 hour of NIV.
* Age over 18

Exclusion Criteria

* Haemodynamic instability after ensuring euvolaemia
* Acute multiple organ failure requiring other organ supportive therapy, including indication for intubation and mechanical ventilation
* Known allergy/intolerance of heparin including known heparin induced thrombosis and thrombocytopaenia
* Acute uncontrolled haemorrhage
* Intracerebral haemorrhage
* Recent (\<6 months) ischaemic cerebrovascular accident
* Organ transplant recipient
* Expected to die within 24 hours
* Venous abnormality or body habitus precluding cannulation
* Contraindication to NIV (as per British Thoracic Society recommendation)

* Facial burns/trauma/recent facial or upper airway surgery
* Vomiting
* Fixed upper airway obstruction
* Undrained pneumothorax
* Recent upper gastrointestinal surgery
* Inability to protect the airway
* Life threatening hypoxaemia (PaO2/FiO2 \<20kPa)
* Bowel obstruction
* Patient refusal
* Pregnancy
* Severe hepatic failure (ascites, hepatic encephalopathy or bilirubin \>100umol/L)
* Severe chronic cardiac failure (NYHA class III or IV)
* Bleeding diathesis (INR\>1.5, platelets \<80,000) in the absence of anticoagulation therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No